Theranostic targeting of CUB domain containing protein 1 (CDCP1) in multiple subtypes of bladder cancer
CLINICAL CANCER RESEARCH
January 2023
Despite recent approvals for checkpoint inhibitors and antibody drug conjugates targeting NECTIN4 or TROP2, metastatic bladder cancer (BC) remains incurable and new treatment strategies are urgently needed. CUB domain containing protein 1 (CDCP1) is a cell surface protein and promising drug target for many cancers. This study aimed to determine whether CDCP1 is expressed in BC and whether CDCP1 can be targeted for treatment with radiolabeled antibodies.